Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
61 hedge funds and large institutions have $32M invested in Astria Therapeutics in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 18 reducing their positions, and 15 closing their positions.
181% more call options, than puts
Call options by funds: $3.82M | Put options by funds: $1.36M
115% more capital invested
Capital invested by funds: $14.9M → $32M (+$17.1M)
17% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 18
12.69% more ownership
Funds ownership: 34.59% → 47.28% (+13%)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
2% less funds holding
Funds holding: 62 → 61 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$5.82M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.9M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.33M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.2M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$611K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.56M |
| 2 |
EP
Eversept Partners
New York
|
-$1.12M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$452K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$402K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$291K |
ATXS Hedge Fund Activity: Q1 2021 in Review
61 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2021, worth a combined $32M — up 115% from $14.9M a quarter earlier.
Fund positioning in ATXS was balanced in Q1 2021: 15 funds opened new positions, 15 closed out, 21 added to existing stakes and 18 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $5.82M. The largest seller was Morgan Stanley, cutting an estimated $1.56M.
- 61 institutional investors held Astria Therapeutics (ATXS) as of Q1 2021, down from 62 in Q4 2020.
- Funds reported $32M of Astria Therapeutics stock for Q1 2021, up 115% quarter-over-quarter.
- 15 funds opened new Astria Therapeutics positions in Q1 2021 and 15 closed out, a net change of 0 holders.
- The largest Astria Therapeutics buyer in Q1 2021 was Perceptive Advisors, an estimated $5.82M added.
- The largest Astria Therapeutics seller in Q1 2021 was Morgan Stanley, an estimated $1.56M sold.
Based on aggregated 13F filings for Q1 2021.